Congenital disorders
The cardio-renal-metabolic connection: a review of the evidence
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
Google Scholar
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342–56.
Google Scholar
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–33.
Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the translational research committee of the heart failure association-European society of cardiology. Eur Heart J. 2018;39:4243–54.
Google Scholar
Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail. 2018;20:853–72.
Google Scholar
Usman MS, Khan MS, Butler J. The interplay between diabetes, cardiovascular disease, and kidney disease. ADA Clin Compend. 2021;2021:13–8.
Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455–69.
Google Scholar
Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease. Circulation. 2021;143:1157–72.
Google Scholar
Kadowaki T, Maegawa H, Watada H, Yabe D, Node K, Murohara T, et al. Interconnection between cardiovascular, renal and metabolic disorders: a narrative review with a focus on Japan. Diabetes Obes Metab. 2022;24:2283–96.
Google Scholar
The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.
Google Scholar
Kodama S, Fujihara K, Horikawa C, Sato T, Iwanaga M, Yamada T, et al. Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis. ESC Heart Fail. 2020;7:2146–74.
Google Scholar
Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. 2015;3:136–45.
Google Scholar
Amato L, Paolisso G, Cacciatore F, Ferrara N, Ferrara P, Canonico S, et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab. 1997;23:213–8.
Google Scholar
Preiss D, Zetterstrand S, McMurray JJV, Östergren J, Michelson EL, Granger CB, et al. Predictors of development of diabetes in patients with chronic heart failure in the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Diabetes Care. 2009;32:915–20.
Google Scholar
Geiss LS, Wang J, Cheng YJ, Thompson TJ, Barker L, Li Y, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980–2012. JAMA. 2014;312:1218–26.
Google Scholar
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–85.
Google Scholar
Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996;77:1017–20.
Google Scholar
Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699–703.
Google Scholar
Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25:121–32.
Google Scholar
Shen Y, Cai R, Sun J, Dong X, Huang R, Tian S, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine. 2017;55:66–76.
Google Scholar
Kuznik A, Mardekian J, Tarasenko L. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010. BMC Nephrol. 2013;14:132.
Google Scholar
Titze S, Schmid M, Kottgen A, Busch M, Floege J, Wanner C, et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant. 2015;30:441–51.
Google Scholar
Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study. Clin Exp Nephrol. 2019;23:85–98.
Google Scholar
Jepson C, Hsu JY, Fischer MJ, Kusek JW, Lash JP, Ricardo AC, et al. Incident type 2 diabetes among individuals with CKD: findings from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2019;73:72–81.
Google Scholar
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease. Hypertension. 2003;42:1050–65.
Google Scholar
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England J Med. 2004;351:1296–305.
Google Scholar
Fried LF, Shlipak MG, Crump C, Kronmal RA, Bleyer AJ, Gottdiener JS, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003;41:1364–72.
Google Scholar
George LK, Koshy SKG, Molnar MZ, Thomas F, Lu JL, Kalantar-Zadeh K, et al. Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function. Circ Heart Fail. 2017. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003825.
Google Scholar
Opie LH, Parving HH. Diabetic nephropathy. Circulation. 2002;106:643–5.
Google Scholar
Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K, et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduct Target Ther. 2023;8:152.
Google Scholar
Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93:137–88.
Google Scholar
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.
Google Scholar
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.
Google Scholar
Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1–14.
Google Scholar
Lombardi C, Spigoni V, Gorga E, Dei CA. Novel insight into the dangerous connection between diabetes and heart failure. Herz. 2016;41:201–7.
Google Scholar
Lim HS, MacFadyen RJ, Lip GYH. Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch Intern Med. 2004;164:1737–48.
Google Scholar
Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120–6.
Google Scholar
Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.
Google Scholar
Suhara T, Baba Y, Shimada BK, Higa JK, Matsui T. The mTOR signaling pathway in myocardial dysfunction in type 2 diabetes mellitus. Curr Diab Rep. 2017;17:38.
Google Scholar
Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Investig. 2011;121:2197–209.
Google Scholar
Li Y, Liu B, Li Y, Jing X, Deng S, Yan Y, et al. Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019;18:3.
Google Scholar
Iacobellis G. Epicardial adipose tissue in endocrine and metabolic diseases. Endocrine. 2014;46:8–15.
Google Scholar
Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22:450–7.
Google Scholar
Sacks HS, Fain JN, Cheema P, Bahouth SW, Garrett E, Wolf RY, et al. Inflammatory genes in Epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes. Diabetes Care. 2011;34:730–3.
Google Scholar
Iacobellis G, Barbaro G. Epicardial adipose tissue feeding and overfeeding the heart. Nutrition. 2019;59:1–6.
Google Scholar
Christensen RH, von Scholten BJ, Lehrskov LL, Rossing P, Jørgensen PG. Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes? Ther Adv Endocrinol Metab. 2020;11:1–16.
Fadini GP, Boscaro E, de Kreutzenberg S, Agostini C, Seeger F, Dimmeler S, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care. 2010;33:1097–102.
Google Scholar
Fadini GP, Albiero M, de Vigili KS, Boscaro E, Cappellari R, Marescotti M, et al. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care. 2013;36:943–9.
Google Scholar
Fadini GP, Mehta A, Dhindsa DS, Bonora BM, Sreejit G, Nagareddy P, et al. Circulating stem cells and cardiovascular outcomes: from basic science to the clinic. Eur Heart J. 2020;41:4271–82.
Google Scholar
Fadini GP, Albiero M. Impaired hematopoietic stem/progenitor cell traffic and multi-organ damage in diabetes. Stem Cells. 2022;40:716–23.
Google Scholar
Rigato M, Bittante C, Albiero M, Avogaro A, Fadini GP. Circulating progenitor cell count predicts microvascular outcomes in type 2 diabetic patients. J Clin Endocrinol Metab. 2015;100:2666–72.
Google Scholar
Fadini GP, Rigato M, Cappellari R, Bonora BM, Avogaro A. Long-term prediction of cardiovascular outcomes by circulating CD34+ and CD34+CD133+ stem cells in patients with type 2 diabetes. Diabetes Care. 2017;40:125–31.
Google Scholar
Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic Vasculopathy. Arterioscler Thromb Vasc Biol. 2006;26:2140–6.
Google Scholar
Rigato M, Avogaro A, Fadini GP. Levels of circulating progenitor cells, cardiovascular outcomes and death. Circ Res. 2016;118:1930–9.
Google Scholar
Poulsom R, Forbes SJ, Hodivala-Dilke K, Ryan E, Wyles S, Navaratnarasah S, et al. Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol. 2001;195:229–35.
Google Scholar
Berezin AE, Kremzer AA, Samura TA, Berezina TA, Martovitskaya YV. Serum uric acid predicts declining of circulating proangiogenic mononuclear progenitor cells in chronic heart failure patients. J Cardiovasc Thorac Res. 2014;6:153–62.
Google Scholar
Fadini GP. A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia. 2014;57:4–15.
Google Scholar
Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction Implications for the syndrome of insulin resistance. J Clin Investig. 1996;97:2601–10.
Google Scholar
Yokota T, Kinugawa S, Yamato M, Hirabayashi K, Suga T, Takada S, et al. Systemic oxidative stress is associated with lower aerobic capacity and impaired skeletal muscle energy metabolism in patients with metabolic syndrome. Diabetes Care. 2013;36:1341–6.
Google Scholar
Bilak JM, Alam U, Miller CA, McCann GP, Arnold JR, Kanagala P. Microvascular dysfunction in heart failure with preserved ejection fraction: pathophysiology assessment, prevalence and prognosis. Card Fail Rev. 2022. https://doi.org/10.15420/cfr.2022.12.
Google Scholar
Kinugawa S, Takada S, Matsushima S, Okita K, Tsutsui H. Skeletal muscle abnormalities in heart failure. Int Heart J. 2015;56:475–84.
Google Scholar
Moriconi D, Sacchetta L, Chiriacò M, Nesti L, Forotti G, Natali A, et al. Glomerular hyperfiltration predicts kidney function decline and mortality in type 1 and type 2 diabetes: a 21-year longitudinal study. Diabetes Care. 2023;46:845–53.
Google Scholar
Gérard AO, Laurain A, Favre G, Drici MD, Esnault VLM. Activation of the tubulo-glomerular feedback by SGLT2 inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: toward the end of a myth? Diabetes Care. 2022;45:148–9.
Sena CM, Pereira AM, Seiça R. Endothelial dysfunction—a major mediator of diabetic vascular disease. Biochimica et Biophysica Acta BBA Molr Basis of Dis. 2013;1832:2216–31.
Google Scholar
Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids. 2010;45:907–14.
Google Scholar
Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002. https://doi.org/10.1186/1475-2840-1-1.
Google Scholar
Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126:1477–500.
Google Scholar
Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American heart association and the heart failure society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140:e294-324.
Google Scholar
Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36:1718–27.
Google Scholar
Lebeche D, Davidoff AJ, Hajjar RJ. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med. 2008;5:715–24.
Google Scholar
Basta G, Schmidt A, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63:582–92.
Google Scholar
Fineberg D, Jandeleit-Dahm KAM, Cooper ME. Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol. 2013;9:713–23.
Google Scholar
Premaratne E, Verma S, Ekinci EI, Theverkalam G, Jerums G, MacIsaac RJ. The impact of hyperfiltration on the diabetic kidney. Diabetes Metab. 2015;41:5–17.
Google Scholar
Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008;74:22–36.
Google Scholar
Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011;300:R1009–22.
Google Scholar
Marshall CB. Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic? Am J Physiol Renal Physiol. 2016;311:F831–43.
Google Scholar
Lewko B, Stepinski J. Hyperglycemia and mechanical stress: targeting the renal podocyte. J Cell Physiol. 2009;221:288–95.
Google Scholar
Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC. From fibrosis to sclerosis. Diabetes. 2008;57:1439–45.
Google Scholar
DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021;17:319–34.
Google Scholar
Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, et al. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2015;3:382–91.
Google Scholar
Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G, et al. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian diabetes society and the Italian society of nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function. J Nephrol. 2020;33:9–35.
Google Scholar
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39.
Google Scholar
Braam B, Joles JA, Danishwar AH, Gaillard CA. Cardiorenal syndrome—current understanding and future perspectives. Nat Rev Nephrol. 2014;10:48–55.
Google Scholar
Raina R, Nair N, Chakraborty R, Nemer L, Dasgupta R, Varian K. An update on the pathophysiology and treatment of cardiorenal syndrome. Cardiol Res. 2020;11:76–88.
Google Scholar
Kim J-A, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction. Circulation. 2006;113:1888–904.
Google Scholar
Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22:423–36.
Google Scholar
Parsonage W, Hetmanski D, Cowley A. Differentiation of the metabolic and vascular effects of insulin in insulin resistance in patients with chronic heart failure. Am J Cardiol. 2002;89:696–703.
Google Scholar
Swan J, Walton C, Godsland I, Clark A, Coats A, Oliver M. Insulin resistance in chronic heart failure. Eur Heart J. 1994;15:1528–32.
Google Scholar
Palazzuoli A, Iacoviello M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev. 2022;28:585–96.
Google Scholar
Tenenbaum A, Fisman EZ. Impaired glucose metabolism in patients with heart failure. Am J Cardiovasc Drugs. 2004;4:269–80.
Google Scholar
Hayden MR, Tyagi SC. Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit. 2003;9:SR35-52.
Google Scholar
Kostis J, Sanders M. The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens. 2005;18:731–7.
Google Scholar
Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;23:463–73.
Google Scholar
Andreozzi F, Laratta E, Sciacqua A, Perticone F, Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser 312 and Ser 616 in human umbilical vein endothelial cells. Circ Res. 2004;94:1211–8.
Google Scholar
Chan SMH, Lau YS, Miller AA, Ku JM, Potocnik S, Ye JM, et al. Angiotensin II causes β-cell dysfunction through an ER stress-induced proinflammatory response. Endocrinology. 2017;158:3162–73.
Google Scholar
Hayden MR, Sowers JR. Isletopathy in type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress. Antioxid Redox Signal. 2007;9:891–910.
Google Scholar
Coué M, Moro C. Natriuretic peptide control of energy balance and glucose homeostasis. Biochimie. 2016;124:84–91.
Google Scholar
Undank S, Kaiser J, Sikimic J, Düfer M, Krippeit-Drews P, Drews G. Atrial natriuretic peptide affects stimulus-secretion coupling of pancreatic β-cells. Diabetes. 2017;66:2840–8.
Google Scholar
Schlueter N, de Sterke A, Willmes DM, Spranger J, Jordan J, Birkenfeld AL. Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. Pharmacol Ther. 2014;144:12–27.
Google Scholar
Díez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail. 2017;19:167–76.
Google Scholar
de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008;582:97–105.
Google Scholar
Suthahar N, Meijers WC, Brouwers FP, Heerspink HJL, Gansevoort RT, van der Harst P, et al. Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population. Int J Cardiol. 2018;250:188–94.
Google Scholar
Perry IJ, Wannamethee SG, Walker MK, Thomson AG, Whincup PH, Shaper AG. Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ. 1995;310:560–4.
Google Scholar
Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;325:147–52.
Google Scholar
Thornley-Brown D. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med. 2006;166:797.
Google Scholar
Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53:1343–7.
Google Scholar
Thomas SS, Zhang L, Mitch WE. Molecular mechanisms of insulin resistance in chronic kidney disease. Kidney Int. 2015;88:1233–9.
Google Scholar
Spoto B, Leonardis D, Parlongo RM, Pizzini P, Pisano A, Cutrupi S, et al. Plasma cytokines, glomerular filtration rate and adipose tissue cytokines gene expression in chronic kidney disease (CKD) patients. Nutr Metab Cardiovasc Dis. 2012;22:981–8.
Google Scholar
Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol. 2016;311:F1087–108.
Google Scholar
Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int. 2005;67:S21–7.
DeFronzo RA, Beckles AD. Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol Endocrinol Metabolism. 1979;236:E328–34.
Google Scholar
Bellasi A, Di Micco L, Santoro D, Marzocco S, De Simone E, Cozzolino M, et al. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease. BMC Nephrol. 2016. https://doi.org/10.1186/s12882-016-0372-x.
Google Scholar
Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–8.
Google Scholar
Sergeev IN, Rhoten WB. 1,25-dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. Endocrinology. 1995;136:2852–61.
Google Scholar
Maestro B, Campiòn J, Dàvlia N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J. 2000;47:383–91.
Google Scholar
Fadda GZ, Akmal M, Premdas FH, Lipson LG, Massry SG. Insulin release from pancreatic islets: effects of CRF and excess PTH. Kidney Int. 1988;33:1066–72.
Google Scholar
Petchey WG, Hickman IJ, Duncan E, Prins JB, Hawley CM, Johnson DW, et al. The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a randomised controlled trial. BMC Nephrol. 2009;10:41.
Google Scholar
Stefíková K, Spustová V, Krivošíková Z, Okša A, Gazdíková K, Fedelešová V, et al. Insulin resistance and vitamin D deficiency in patients with chronic kidney disease stage 2–3. Physiol Res. 2011;60:149–55.
Google Scholar
Lu Y, Wang Y, Sun Y, Li Y, Wang J, Zhao Y, et al. Effects of active vitamin D on insulin resistance and islet β-cell function in non-diabetic chronic kidney disease patients: a randomized controlled study. Int Urol Nephrol. 2022;54:1725–32.
Google Scholar
Lee W, Lee HJ, Jang HB, Kim HJ, Ban HJ, Kim KY, et al. Asymmetric dimethylarginine (ADMA) is identified as a potential biomarker of insulin resistance in skeletal muscle. Sci Rep. 2018;8:2133.
Google Scholar
Koppe L, Pillon NJ, Vella RE, Croze ML, Pelletier CC, Chambert S, et al. p-cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol. 2013;24:88–99.
Google Scholar
D’Apolito M, Du X, Zong H, Catucci A, Maiuri L, Trivisano T, et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Investig. 2010;120:203–13.
Google Scholar
Koppe L, Nyam E, Vivot K, Fox JEM, Dai XQ, Nguyen BN, et al. Urea impairs β cell glycolysis and insulin secretion in chronic kidney disease. J Clin Investig. 2016;126:3598–612.
Google Scholar
Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:1894–900.
Google Scholar
Li Y, Zhang L, Gu Y, Hao C, Zhu T. Insulin resistance as a predictor of cardiovascular disease in patients on peritoneal dialysis. Perit Dial Int. 2013;33:411–8.
Google Scholar
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.
Google Scholar
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.
Google Scholar
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
Google Scholar
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–29.
Google Scholar
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with Finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–63.
Google Scholar
Nagahisa T, Saisho Y. Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Ther. 2019;10:1733–52.
Google Scholar
DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13:11–26.
Google Scholar
Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol. 2021;17:227–44.
Google Scholar
Cherney DZI, Udell JA, Drucker DJ. Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med. 2021;2:1203–30.
Google Scholar
González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med. 2023;55:502–13.
Google Scholar
Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. J Am Coll Cardiol. 2020;75:422–34.
Google Scholar
Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023. https://doi.org/10.1038/s41569-023-00849-3.
Google Scholar
Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20:225.
Google Scholar
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503–15.
Google Scholar
Panico C, Bonora B, Camera A, Chilelli NC, Da PG, Favacchio G, et al. Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review. Cardiovasc Diabetol. 2023;22:164.
Google Scholar
Mann JFE, Buse JB, Idorn T, Leiter LA, Pratley RE, Rasmussen S, et al. Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis. Diabetes Obes Metab. 2021;23:2058–66.
Google Scholar
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.
Google Scholar
Wilson JM, Lin Y, Luo MJ, Considine G, Cox AL, Bowsman LM, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes Metab. 2022;24:148–53.
Google Scholar
Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10:774–85.
Google Scholar
